23andMe Holding Co. (NASDAQ:ME – Get Free Report) saw a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 1,030,000 shares, a drop of 95.2% from the September 30th total of 21,650,000 shares. Currently, 6.7% of the company’s shares are sold short. Based on an average daily volume of 185,800 shares, the days-to-cover ratio is currently 5.5 days.
23andMe Stock Performance
Shares of 23andMe stock traded down $0.18 on Friday, hitting $4.67. The company’s stock had a trading volume of 349,563 shares, compared to its average volume of 263,521. 23andMe has a 1 year low of $4.60 and a 1 year high of $20.40. The firm has a fifty day moving average price of $6.19 and a 200-day moving average price of $8.06. The company has a market capitalization of $2.29 billion, a price-to-earnings ratio of -3.34 and a beta of 1.20.
23andMe (NASDAQ:ME – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($2.80) earnings per share for the quarter. 23andMe had a negative return on equity of 83.22% and a negative net margin of 317.03%. The company had revenue of $40.41 million for the quarter, compared to analyst estimates of $50.30 million.
Institutional Inflows and Outflows
Analyst Ratings Changes
Separately, TD Cowen cut 23andMe from a “strong-buy” rating to a “strong sell” rating in a research report on Wednesday, August 7th.
Check Out Our Latest Report on ME
23andMe Company Profile
23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
Recommended Stories
- Five stocks we like better than 23andMe
- What is Insider Trading? What You Can Learn from Insider Trading
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Pros And Cons Of Monthly Dividend Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Quiet Period Expirations Explained
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for 23andMe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 23andMe and related companies with MarketBeat.com's FREE daily email newsletter.